San Diego, CA — December 9, 2025 — Leads & Copy — Modular Medical, Inc. (NASDAQ:MODD), an insulin delivery technology company, has announced the commencement of an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock. The offering is for the company’s FDA-cleared patch pump designed to target all adult “almost-pumpers” with its user-friendly and affordable design.
The shares of common stock and warrants are immediately separable and will be issued separately but can only be purchased together in this offering.
Modular Medical expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the aggregate number of shares of its common stock and /or warrants sold in the offering. The offering is subject to market and other conditions. There can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All shares of common stock and warrants to be sold in the proposed offering will be sold by Modular Medical.
Newbridge Securities Corporation is acting as the sole bookrunner for the proposed offering.
The offering is being made pursuant to an effective “shelf” registration statement on Form S-3 (File No. 333-287313) previously filed with the Securities and Exchange Commission (the “SEC”) on May 15, 2025 and declared effective by the SEC on May 22, 2025. The securities may be offered only by means of a prospectus. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC. Electronic copies of the preliminary prospectus supplement and accompanying prospectus and, when available, copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained by visiting the SEC’s website at www.sec.gov or by contacting Newbridge Securities Corporation, Attn: Equity Syndicate Department, 1200 North Federal Highway, Suite 400, Boca Raton, Florida 33432, by email at syndicate@newbridgesecurities.com or by telephone at (877) 447-9625.
This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
Modular Medical, Inc. intends to launch the next generation of insulin delivery technology. Using its patented technologies, the Company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Its mission is to improve access to the highest standard of glycemic control for people with diabetes, taking it beyond “superusers” and providing “diabetes care for the rest of us.”
Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump.
Jeb Besser
Chief Executive Officer
Modular Medical, Inc.
+1 (617) 399-1741
IR@modular-medical.com
Source: Modular Medical, Inc.
